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Latin America (LA) is a multicultural region, with an
estimate of just over 600 million inhabitants, displaying
great heterogeneity among their nations. LA countries
exhibit complex demographic characteristics because of
the interaction of factors such as the different ethnic
background of its population, a history of colonialism,
and varying immigration patterns, resulting in a diversi-
fied population that differs in every country within the
region [1].
The LA region has experienced a health transition charac-
terized by fast and complex epidemiological changes in the
past decades, combining increasing rates of non-
communicable diseases and injuries, while keeping uncon-
trolled many existing endemic and emerging diseases.
The national health care systems within the LA area are
heterogeneous in their organizational structure and complex
in their operational configuration, and in the principles guid-
ing the public and private sector roles in the provision of
health care services. In LA, medical attention for rheumatoid
arthritis (RA) faces a dual challenge, on one side, competes
with a budget designed to fight poverty, lack of education, an
increasing number of patients, and on the other hand, the
demographic and epidemiological transitions; the insufficient
number of rheumatologists and concentration of the work-
force in large cities; an insufficient budget for education and
research; and the backlog of accumulated problems character-
istic of underdeveloped societies [2]. In consequence, RA is
not yet considered a public health priority for the national
health care systems, Therefore, explaining why only 56 % of
RA patients had access to full medical health coverage (thus
often excluding biologics), only 58 % had more than 7 years
of education, and 58 % were of a low/low-middle socioeco-
nomic status [3].
Previous efforts has been made to overcome this sit-
uation including: the identification of barriers to health
care [4], promoting access to a prompt diagnosis and
treatment, developing algorithms according these reali-
ties [5], educating patients and doctors [6], or estimating
the economic impact of the disease in the region [7]
and, recently, setting the standards to harmonize the
treatment provided to RA patients in LA, by developing
a program focused in establish centers of excellence that
would offer to RA patients, a better care [8].
Additionally, technological progress, drug development
and diagnostic capabilities, advanced in the past two decades
has resulted in major improvements in health outcomes for
RA patients in developed countries, but the cost of these in-
novations including joint prostheses, access to biological med-
ications and the lack of trained health personnel to deliver the
specialized care, still puts these out of the reach of people with
RA in most low and middle income countries. Education and
training of health professionals also remains an unmet key
priority [2].
The Pan American League of Associations for Rheumatol-
ogy (PANLAR) is an umbrella organization of Rheumatology
National Societies in the American Continent, encompassing
21 countries, of those, 19 nations are located in the LA and
Caribbean region. PANLAR seeks the followingmain goals [9]:
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(a) Foster cooperation between different countries through
existing national societies, organizations and colleges of
Rheumatology and cooperating extensively with interna-
tional organizations such as: EULAR, APLAR, AFLAR
and ILAR.
(b) Promote the educational activities and organize in con-
junction with the national societies the Pan American
Congress of Rheumatology, as well as to promote nation-
al or regional meetings and encourage publication and
dissemination of the scientific proceedings of meetings.
(c) Promote the educational activities and research of the
PANLAR study groups.
(d) Develop new channels of communication among the
member societies and stimulate scientific research into
all aspects of the aims of PANLAR.
With these goals in mind and with the main objective fo-
cused on the revision and updating of the current challenges,
difficulties and barriers faced by LA rheumatologists when
treating RA and to find potential solutions (leverage points)
to overcome the identified barriers, PANLAR is presenting in
this supplement of Clinical Rheumatology nine relevant, chal-
lenging, and updated issues unique to LA region:
& Social and economic impact of RA and its relationship
with health priorities.
& The path in seeking medical care of patients with RA.
& The importance of early diagnosis. Challenges and
solutions.
& Proper management of RA. What the guidelines
recommend?
& Access to optimal treatment. Current situation.
& Education of patients with RA.
& The training of allied health professionals.
& The model of comprehensive care.
& Challenges in LA for the implementation of an ideal mod-
el of health care center in patients with RA: are we ready
to implement?
Each chapter has been developed by a Latin-
American leading expert in the field in association with
a group of experienced rheumatologists as coworkers,
encompassing nine different countries in the region, thus
reflecting the real challenges and opportunities for diag-
nosis and treatment of RA in LA. This review helps us
to increase and improve the knowledge and approaches
to this health condition in the region, thus promoting
equity, quality, and efficiency of RA healthcare. The
review includes not only the burden of the condition
in LA but also its social, educational, and financial re-
lated aspects, furthermore, patient access to care, train-
ing of human resources, and novel approaches to
models of care are analyzed.
Due to the current and future impact from RA in develop-
ing settings, health care systems need to develop coherent
policies and strategies for dealing with this burden. Further
epidemiological and health economics research is urgently
needed [10] in this area and to better inform policy for dealing
with RA in LA, to encourage multiple stakeholders (including
funders, insurers, policy makers, educators, researchers, con-
sumers, and health care givers) to co-operatively develop and
implement efficient models of care to manage RA in develop-
ing countries.
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